- Akoya Biosciences Reports First Quarter 2024 Financial Results
- Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
- Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts
- Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows
- Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
- Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale
- Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook
- Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference
- Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases
- Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.95 |
---|---|
High | 2.11 |
Low | 1.95 |
Bid | 1.97 |
Offer | 1.98 |
Previous close | 1.94 |
Average volume | 965.46k |
---|---|
Shares outstanding | 49.39m |
Free float | 26.09m |
P/E (TTM) | -- |
Market cap | 95.81m USD |
EPS (TTM) | -1.47 USD |
Data delayed at least 15 minutes, as of May 24 2024 17:19 BST.
More ▼